As a gene target, BCL2 received regulation through this FFL, which can be enriched in various pathways, such as the PI3K-AKT signalling pathway and pathways in cancer and hepatitis B, which may hint an ongoing struggle between cell death and survival mechanisms that might alter the immune response in autoimmune condition of MG. This evidence concerns the gene BCL2 and myasthenia gravis.